GDPs Flawed Gauge of Prosperity Spurs Push for Alternative Metrics The Fed May Need to Raise Rates in July to Calm Bond Vigilantes Yardeni Warns Jim Cramer Highlights Diversification Beyond AI at Monthly Portfolio Review Political Scandal Over Film Funding Casts Doubt on Flvio Bolsonaros Presidential Campaign Nikon CEO Reveals Strategy to Challenge ASML with Affordable Chipmaking Equipment Emirates NBD to Launch Open Offer for 26 Stake in RBL Bank Starting June 1 ORI Q1 2026 Earnings EPS Misses Estimates as Operating Environment Challenges Persist DHI Group DHX Q1 2026 Earnings EPS Crushes Estimates by 164 Stock Surges Enlight Renewable Energy Ltd Q1 2026 Earnings Positive EPS Performance Amidst Limited Data Avita Medical Q1 2026 Earnings EPS Miss Clouds Progress Stock Gains ORGN Q4 2025 Earnings Massive EPS Miss Highlights Ongoing Business Restructuring JKHY Q1 2026 Earnings Strong EPS Beat of 1488 Surprises Analysts Red Robin Gourmet Burgers RRGB Dips Further as Stock Tests Key Support Levels Ames National Corporation ATLO Holds Steady as Key Levels Define Trading Range CorMedix CRMD Rises 242 as Momentum Builds Toward Key Resistance Hovnanian Enterprises HOV Slips 886 as Housing Headwinds Intensify Alterity Therapeutics ATHE Rallies as Trading Volume Increases Testing Resistance Territory Kevin Warsh Set to Assume Federal Reserve Chairmanship in White House Ceremony TRIN Q1 2026 Earnings EPS Beats Estimates Stock Edge Higher AgEagle Aerial Systems UAVS Edges Higher Amid Tight Trading Range ARM Q1 2026 Earnings EPS Beat Fails to Lift Shares as Market Weighs Headwinds Investors Title Company ITIC Q4 2025 Earnings Strong EPS Performance Amid Quiet Period ENLV Q4 2025 Earnings Significant EPS Miss Amid Development Stage Costs BTU Q1 2026 Earnings Missed EPS Estimates Amid Challenging Coal Market TXMD Q3 2023 Earnings EPS Misses Estimates by Wide Margin Amidst Operational Challenges QURE Q1 2026 Earnings Narrower Loss Than Expected but Stock Declines on Lack of Revenue Incannex Healthcare IXHL Q1 2026 Earnings Deepening Losses as ClinicalStage Biotech Continues PreRevenue Development